Eye drop recall alert: Over 2.5 million bottles pulled due to possible contamination

Eye Drop Recall Alert: 2.5 Million Bottles Withdrawn Over Contamination Concerns

Theindiapostdaily.com – The U.S. Food and Drug Administration (FDA) has issued a recall alert for more than 2.5 million bottles of a prescription eye medication, following reports of a foreign substance potentially contaminating the product. The Hill highlighted the recall, which affects Prednisolone Acetate Ophthalmic Suspension, USP, 1%, a medication used to address inflammation and allergic reactions in the eyes.

Recall Details and Manufacturer

Lupin Pharmaceuticals Inc. has taken the lead in recalling 2,530,182 bottles of the drug, which is prescribed to alleviate symptoms such as redness, itching, and swelling linked to eye infections or other conditions. The affected product comes in three sizes: 5 mL (NDC 70748-332-02), 10 mL (NDC 70748-332-03), and 15 mL (NDC 70748-332-04). This medication is produced by Lupin Limited in Pithampur, Madhya Pradesh, India.

Reason for the Recall

The FDA cited the possible presence of a foreign substance as the reason for the recall. This issue may lead to temporary health effects that are reversible, though serious consequences are deemed unlikely. The recall spans multiple batch numbers across the various bottle sizes, requiring patients to verify if their prescription falls under the affected lots.

“Prednisolone is a steroid medicine that is used to relieve the redness, itching, and swelling caused by eye infections and other conditions. This medicine is available only with your doctor’s prescription,”

as stated by the Mayo Clinic, which explains the drug’s purpose and prescription-only status. Patients are encouraged to consult their healthcare providers before stopping or switching their medication.

FDA’s Classification and Next Steps

The recall was first announced last month and later categorized by the FDA as a Class II recall last week. Class II recalls target products where “use may cause temporary or medically reversible adverse health consequences,” or where serious outcomes are considered remote. Consumers and medical professionals are advised to review the recall documentation before using the medication. Those who suspect they have a contaminated bottle should seek guidance from their pharmacist or physician.

Lupin Pharmaceuticals Inc. has not yet provided a statement on the recall, according to the latest report. This development underscores ongoing efforts by regulatory bodies to ensure the safety of pharmaceuticals, especially those used in delicate areas like the eyes.